Dry eye syndrome

Uni-Bio Science Group Announces 2023 Annual Results

Retrieved on: 
Wednesday, April 10, 2024
Escherichia coli, Gel, Prevalence, FN, Hip, Risk, Patient, Janet Woodcock, EGF, KL1, Yoy, Wound healing, Osteoporosis, CMO, Marketing, Dry eye syndrome, Government, Wrist, Genetic engineering, Ageing, Ophthalmology, Fine chemical

[27 March 2024 – Hong Kong] A fully integrated biopharmaceutical company – Uni-Bio Science Group Limited (“Uni-Bio Science”, together with its subsidiaries referred to as the “Group”, stock code: 0690.HK), is pleased to announce its annual results for the year ended 31 December 2023 (the “Year”).

Key Points: 
  • [27 March 2024 – Hong Kong] A fully integrated biopharmaceutical company – Uni-Bio Science Group Limited (“Uni-Bio Science”, together with its subsidiaries referred to as the “Group”, stock code: 0690.HK), is pleased to announce its annual results for the year ended 31 December 2023 (the “Year”).
  • The Group reached a significant milestone with the successful introduction of Skbrella™ FN, marking its entry into the advanced skincare raw material market.
  • In 2023, the Group recorded a revenue of approximately HK$484.7 million, representing an increase of 10.1 % YoY.
  • The Group strictly controlled its general and administrative expenses, which only accounted for 9.8% of revenue in 2023 as compared with 10.7% in 2022.

Verana Health Developing Qdata® Dry Eye Disease, the Largest Real-World Dataset of its Kind

Retrieved on: 
Thursday, April 4, 2024
Prevalence, Dry eye syndrome, ASCRS, SAN, Patient, Ophthalmology, Research, RWD, American Academy, Cataract, DED, Society, Data, Telecanthus, Health, Annual general meeting, Nursing

Qdata DED represents a significant advancement in ophthalmology research, and is the largest of its kind, featuring an extensive dataset that will include outcomes and clinical information on more than 10 million de-identified patients with DED and related ocular conditions.

Key Points: 
  • Qdata DED represents a significant advancement in ophthalmology research, and is the largest of its kind, featuring an extensive dataset that will include outcomes and clinical information on more than 10 million de-identified patients with DED and related ocular conditions.
  • “We’re harnessing the power of real-world evidence to transform patient care and expedite the development of crucial therapies,” said Sujay Jadhav, CEO of Verana Health.
  • Dry eye disease affects nearly 16 million Americans , posing significant challenges for patients and ophthalmologists alike.
  • Verana Health remains at the forefront of this transformation, continuously expanding its Qdata offerings to meet the growing needs of life sciences teams and clinicians.

OASIS Medical Inc. Brings a New Shape to Punctal Occlusion

Retrieved on: 
Saturday, April 6, 2024
Plug-in (computing), Oasis, ASCRS, OASIS, Catalog, Dry eye syndrome, Birth control

GLENDORA, Calif., April 6, 2024 /PRNewswire/ -- OASIS® Medical Inc., manufacturer and distributor of disposable surgical solutions and dry eye solution brands Oasis TEARS® and SOFT PLUG® punctal plugs launch the SOFT PLUG® Extended Duration 180-T Tapered Plug at ASCRS booth 2675 in Boston.

Key Points: 
  • SOFT PLUG® Extended Duration 180-T Tapered Plugs are designed with a .25mm tapered end for ease of insertion into the punctal opening.
  • The plug then gradually widens to a .6mm diameter at the top end to contribute to occlusion of the canaliculus.
  • SOFT PLUG® Extended Duration 180-T Tapered Plugs are intended to temporarily block tear drainage by the occlusion of the canaliculus to temporarily treat dry eye syndrome and the dry eye components of various ocular surface diseases.
  • The addition of SOFT PLUG® Extended Duration 180-T Tapered Plug to OASIS line of dry eye solutions brings a robust selection of punctal occlusion to eye care providers in the US.

Dry Eye Syndrome Market Set for Rapid Growth as Aging Population Demand Soars - Global Long-term Forecast to 2028 and 2032 - ResearchAndMarkets.com

Retrieved on: 
Friday, April 5, 2024
General Health, Pharmaceutical, Optical, Health, Diagnosis, Quality of life, DES, Research, Growth, Prevalence, Dry eye syndrome, Acquisition, Therapy, Ageing, Pharmaceutical industry

The "Dry Eye Syndrome Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Dry Eye Syndrome Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.
  • Leveraging in-depth market data, the report delves into the extensive range of products designed to alleviate symptoms of Dry Eye Syndrome (DES), including innovative liquid drops, gel formulations, and advanced ointment solutions.
  • These developments reflect the market's response to growing global demand, providing relief and effective therapy for those affected by the condition.
  • Moreover, the report lends insight into the geographical nuances that manifest in the demand and service provision within the global Dry Eye Syndrome sector.

Bausch + Lomb Will Present New Scientific Data and Analyses at the American Society of Cataract and Refractive Surgery Annual Meeting

Retrieved on: 
Wednesday, March 27, 2024
Science, Other Science, Research, Pharmaceutical, Optical, Surgery, General Health, Health, Momentum, YAG, Toric, Failure, IOP, Retinal, Glaucoma, Exercise, DSM-IV codes, Neuropathic pain, ASCRS, History, Sale, Contact, Dry, Refraction, Bausch & Lomb, Eye, System, Keratoconus, Medication discontinuation, Pain, Corneal topography, Telecanthus, Astigmatism, Aphakia, Correction, Uveitis, Surgeon, Diabetes, Risk, Eye injury, CTK, Retinal detachment, Side, Trial of the century, Visual acuity, Diagnosis, Safety, Contraindication, Emmetropia, Vision, Taste, Dry eye syndrome, Intraocular lens, Presbyopia, Real, Floater, Magnetic resonance, Contrast (vision), Human, GLARE, Infection, Use, FDA, Ranibizumab, Muscular dystrophy, Sickle cell disease, Refractive surgery, Retina, Direction, IDE, Allergy, User, Society, Bleeding, Autoimmune disease

In addition to these scientific presentations, the company will also sponsor educational events focused on these and other Bausch + Lomb products.

Key Points: 
  • In addition to these scientific presentations, the company will also sponsor educational events focused on these and other Bausch + Lomb products.
  • Bausch + Lomb activities at ASCRS:
    “Assessment of the Spectacle Independence and Visual Outcomes Following Bilateral Implantation of a Novel Toric IOL* Among Cataract Patients.” Harasymowycz et al.
  • “Outcomes of an Ultra-Low Cylinder Powered (0.90 D) Toric versus Non-Toric IOL in Low Astigmatic Patients Undergoing Cataract Surgery.” Muzychuk et al.
  • “Quality of Vision and Clinical Outcomes of a Novel Trifocal IOL* Implanted Bilaterally After Cataract Surgery: A Canadian Multicenter Study.” Harasymowycz et al.

Surface Ophthalmics Announces New Leadership with Richard Lindstrom, MD, and Renewed Vision for Addressing Critical Unmet Needs of Dry Eye Syndrome Patients

Retrieved on: 
Wednesday, March 13, 2024
Biotechnology, Pharmaceutical, Optical, Health, International Society, Partnership, DES, ASCRS, Patient, Ophthalmology, Surface, University, Dry, MD, Refraction, Cataract, Eye, Mycophenolic acid, Society, Dry eye syndrome, Lead, Pharmaceutical industry

Surface Ophthalmics , a pioneering biopharmaceutical company, dedicated to transforming the management and treatment of dry eye syndrome (DES), today announced the appointment of Richard Lindstrom, MD as Founder & Chairman.

Key Points: 
  • Surface Ophthalmics , a pioneering biopharmaceutical company, dedicated to transforming the management and treatment of dry eye syndrome (DES), today announced the appointment of Richard Lindstrom, MD as Founder & Chairman.
  • A highly acclaimed physician and surgeon in ophthalmology, Dr. Lindstrom is founder and attending surgeon emeritus at Minnesota Eye Consultants, P.A.
  • Dr. Lindstrom will lead in partnership with Surface’s distinguished Board of Directors including Adrienne Graves, Ph.D., (Lead Director); Perry J. Sternberg, Shelley Thunen, and J. Andy Corley.
  • Dr. Richard Lindstrom is founder and attending surgeon emeritus at Minnesota Eye Consultants P.A., a provider of eye care services, since 1989.

Prevent Blindness Provides Free Resources as Part of April's Women's Eye Health and Safety Month to Educate Women on Necessary Steps to Help Save Sight

Retrieved on: 
Wednesday, March 27, 2024
Orbis, IOP, Pigment, Glaucoma, Le Bonheur Children's Hospital, Social media, Pressure, Visual impairment, Contact, Paratriathlon, Intraocular pressure, AAO, Policy, Orbis International, Hormone, Diabetes, Risk, Mental health, Delta Gamma, NIH, Eyelid, Prevalence, Eye, Associate, Safety, Cataract, Menopause, University, Pregnancy, Hospital, Melasma, Public health, Lactation, Puberty, American Academy, Lens, Telecanthus, Eye disease, Graves' ophthalmopathy, Bangladesh Technical Education Board, Dry eye syndrome, Pediatrics, Birth control

CHICAGO, March 27, 2024 /PRNewswire-PRWeb/ -- Prevent Blindness, the nation's leading nonprofit eye health organization, has declared April as Women's Eye Health and Safety Month. According to Orbis International, globally there are 112 million more women than men living with vision loss, including blindness. Prevent Blindness is offering free resources, including fact sheets, shareable social media graphics, educational videos and web pages, on a range of eye health issues that predominantly affect women.

Key Points: 
  • CHICAGO, March 27, 2024 /PRNewswire-PRWeb/ -- Prevent Blindness , the nation's leading nonprofit eye health organization, has declared April as Women's Eye Health and Safety Month.
  • Prevent Blindness is offering free resources, including fact sheets, shareable social media graphics, educational videos and web pages, on a range of eye health issues that predominantly affect women.
  • Women have a higher prevalence of age-related macular degeneration, cataract, dry eye, glaucoma, refractive error and thyroid eye disease.
  • For more information on women's eye health topics, including fact sheets on eye diseases and eye safety, please visit PreventBlindness.org.

 Marketing application of Diquafosol Sodium eye drops has been officially accepted by the China National Medical Products Administration (NMPA)

Retrieved on: 
Tuesday, January 30, 2024
Telecanthus, Patient, Dry eye syndrome, Ophthalmology, BFS, API, Marketing, Growth, Fine chemical

This acceptance marks a pivotal step in expanding the Group’s ophthalmology drug repertoire and providing patients with more diverse treatment options upon successful marketing approval.

Key Points: 
  • This acceptance marks a pivotal step in expanding the Group’s ophthalmology drug repertoire and providing patients with more diverse treatment options upon successful marketing approval.
  • Diquafosol Sodium eye drops complement the Group's robust ophthalmic drug portfolio, following GeneSoft®, which is expected to be approved for marketing in the first quarter of 2025.
  • Aligned with the surging demand within China's ophthalmic drug market, the Group identifies the significant potential, as over 360 million patients suffer from dry eye disease in the country.
  • This site is primed for the production of Diquafosol Sodium eye drops, employing the latest Blow-Fill-Seal (BFS) technology to ensure a seamless, aseptic process from bottle creation to filling and sealing.

Leading with Clarity: BOSA Equips Eye Doctors for Booming Dry Eye Market

Retrieved on: 
Tuesday, January 16, 2024
OSD, Optometry, Eye, Patient, MD, Dry eye syndrome, Ophthalmology, Multimedia, Interferometry, Documentation, Telecanthus, Demodex, Disease, White, Therapy, Gland, OD, Education, M&S, Telescopic sight

NILES, Ill., Jan. 16, 2024 /PRNewswire-PRWeb/ -- M&S Technologies, a leader in computerized vision testing in collaboration with Bruder Healthcare, renowned for dry eye solutions announce the launch of the M&S Bruder Ocular Surface Analyzer (BOSA). The all-in-one innovative device represents an advancement in dry eye assessment and is poised to be a necessity for eye care practices treating ocular surface disease (OSD), including dry eye syndrome. In only 15 seconds per eye, BOSA captures and provides OSD test results. "With the system's unmatched speed, accuracy, and ease of use, doctors can manage dry eye patients more efficiently and effectively, improving outcomes through better data and boosting revenues through time savings," explains Brent Jones of Hilco Vision, parent company of M&S Technologies and Bruder Healthcare.

Key Points: 
  • The all-in-one innovative device represents an advancement in dry eye assessment and is poised to be a necessity for eye care practices treating ocular surface disease (OSD), including dry eye syndrome.
  • "The Bruder Ocular Surface Analyzer is the most comprehensive "one-stop" instrument available to document Dry Eye Disease."
  • BOSA consolidates these diverse tests into one efficient device, offering eye doctors a comprehensive solution within their exam rooms.
  • It is the answer for both the established Dry Eye practice looking to improve efficiency and the eye care practice looking to start a Dry Eye clinic," said Darrell White, MD of SkyVision Centers.

Bausch + Lomb Receives FDA Approval for TENEO™ Excimer Laser Platform for Myopia and Myopic Astigmatism LASIK Vision Correction Surgery

Retrieved on: 
Monday, January 8, 2024
FDA, General Health, Optical, Health, IOP, Telecanthus, Patient, Ophthalmology, Failure, Corneal topography, Food, Autoimmune disease, Contraindication, Risk, Floater, Sale, Near-sightedness, CTK, Pain, Retinal detachment, User, Bleeding, Surgeon, Diabetes, Dry, Eye, Side, Dry eye syndrome, Posture, Laser, Visual acuity, Neuropathic pain, Engineering, Infection, Use, Keratoconus, Safety, Magnetic resonance, Bausch & Lomb, Glaucoma, Hospital

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. Food and Drug Administration (FDA) has approved the TENEO Excimer Laser Platform for laser-assisted in situ keratomileusis (LASIK) vision correction surgery for myopia and myopic astigmatism (nearsightedness and nearsightedness with astigmatism)*.

Key Points: 
  • Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. Food and Drug Administration (FDA) has approved the TENEO Excimer Laser Platform for laser-assisted in situ keratomileusis (LASIK) vision correction surgery for myopia and myopic astigmatism (nearsightedness and nearsightedness with astigmatism)*.
  • This feature helps to ensure the laser ablation pattern is not negatively impacted by a patient's eye movement and helps achieve outstanding post-operative outcomes.
  • The platform’s high-speed laser operates at 500Hz, the fastest ablation time of all excimer lasers available in the United States at approximately 1.2 seconds per diopter.
  • “FDA approval of TENEO represents a major milestone for the advancement of laser vision correction technology in the United States,” said George Waring IV, M.D., ophthalmologist and founder and medical director, Waring Vision Institute, Mt.